IMNN-001 + bevacizumab + carboplatin + paclitaxel

This combination consists of IMNN-001 (also known as GEN-1), bevacizumab, carboplatin, and paclitaxel, investigated primarily for the treatment of advanced epithelial ovarian cancer. **IMNN-001** is a DNA-based immunotherapeutic (interleukin-12 gene therapy) formulated for intraperitoneal administration to stimulate a local immune response, designed using Imunon's TheraPlas platform[1][3][7]. **Bevacizumab** is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A) to inhibit angiogenesis[2][6]. **Carboplatin** is a platinum-based chemotherapy agent that induces DNA crosslinking and cell death, while **paclitaxel** is a microtubule inhibitor that interrupts cell division. The combination is designed to integrate direct cytotoxicity from carboplatin and paclitaxel, immune activation from IMNN-001, and anti-angiogenic effects from bevacizumab, aiming to improve clinical outcomes in ovarian cancer[1][5][3]. The regimen is usually administered with IMNN-001 given intraperitoneally, while the others are given intravenously.

Other names

GEN-1GEN1GEN 1IMNN-001IMNN001IMNN 001bevacizumabcarboplatinpaclitaxel